At its meeting on 16 January 2023 the Transparency Council adopted opinion No. 11/2023 on the evaluation of the medicine Keytruda (pembrolizumab) under the drug programme: “Treatment of patients with breast cancer (ICD-10: C50)”.
At its meeting on 16 January 2023 the Transparency Council adopted opinion No. 11/2023 on the evaluation of the medicine Keytruda (pembrolizumab) under the drug programme: “Treatment of patients with breast cancer (ICD-10: C50)”.